Business
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
RAHWAY, N.J., February 25, 2026--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug Administration (FDA) approval of NUMELVI™ (atinvicitinib tablets) – the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The product is expected to be a
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/36a941904ec0da9c42e929ba43bb8f69"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5X6Co1hBSBEDJpddbm_srw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/36a941904ec0da9c42e929ba43bb8f69","width":480,"height":240}},"lazy":false},{"type":"text","content":"The only JAK inhibitor approved in the U.S. for the control of pruritus associated with allergic dermatitis in dogs six months of age and older","length":143,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., February 25, 2026--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug Administration (FDA) approval of NUMELVI™ (atinvicitinib tablets) – the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The product is expected to be available at veterinary clinics and hospitals nationwide in spring 2026.","length":592,"tagName":"p"},{"type":"text","content":""Merck Animal Health is proud to introduce NUMELVI, our latest advancement geared at rapidly controlling pruritus associated with allergic dermatitis, a common condition that causes distress for so many pets and pet owners," said Christine McKinney, DVM, DACVD and Senior Professional Services Veterinarian, Merck Animal Health.","length":338,"tagName":"p"},{"type":"text","content":""With more than 70 years of innovation and commitment to animal health, we are confident that NUMELVI will offer veterinary professionals a groundbreaking, first-of-its-kind solution aimed at improving the health and well-being of dogs – from as young as six months to mature dogs – and ultimately providing peace of mind for the people who care for them," added McKinney. "NUMELVI also offers added convenience for veterinary clinics; most dogs, starting at weights as low as 4.4 pounds, require only one or half of a tablet, and there is no need to adjust vaccination schedules. Plus, NUMELVI ...